Abstract:
Objective
To observe the efficacy and safety of voriconazole in the treatment of invasive pulmonary fungal infection in children with leukemia.
Methods
Forty-three children with invasive pulmonary fungal infection were randomly divided into observation group(n=22) and control group(n=21).The control group was treated with amphotericin B and the observation group was treated with voriconazole. The clinical efficacy, bacterial clearance and adverse reactions (liver damage, hypokalemia, renal damage, phlebitis and gastrointestinal reactions) were compared between the two groups.
Results
The total effective rate and bacterial clearance rate of the observation group were 81.8%(18/22) and 86.4%(19/22) respectively, which were significantly higher than those of the control group ［52.4%(11/22),57.1%(12/21)］, the difference being statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.6%(3/22), which was significantly lower than that in the control group(42.9%, 9/21), the difference being statistically significant(P<0.05).
Conclusion
Voriconazole, as a drug for invasive pulmonary fungal infection in children, is safe and effective and deserves to be widely used clinically.

Key words: Leukemia, Invasive pulmonary fungal infection, Voriconazole, Children